金斯瑞生物科技(01548.HK):傳奇生物一季度實現收益1370萬美元
格隆匯5月18日丨金斯瑞生物科技(01548.HK)發佈公吿,上市附屬公司傳奇生物科技股份有限公司發佈截至2021年3月31日止第一季度的未經審核財務業績,該期內的收益為1370萬美元,而上年同期為1150萬美元。增加220萬美元主要是由於根據傳奇生物與楊森的協議確認的額外里程碑款項。
截至2021年3月31日止三個月的研發開支為7110萬美元,而上年同期為4800百萬美元。增加2310萬美元主要是由於臨牀試驗數量增加、參加有關試驗的患者人數增加及研發候選產品數量增加。於2021年3月31日,傳奇生物有現金及現金等價物約4.123億美元及定期存款約5000萬美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.